晚期平滑肌肉瘤的二线内科治疗
孙元珏
姚阳
1.200233,上海交通大学附属第六人民医院肿瘤内科2.200233,上海交通大学附属第六人民医院肿瘤内科
摘要：Leiomyosarcoma ( LMS ) is a sort of usual aggressive soft-tissue sarcoma ( STS ),accounting for 5％-10％of all the STS.Local recurrence and distant metastasis may happen after operations in LMS,while lung and liver are the most common metastatic organs.Medical treatment is the most important method for advanced LMS without the opportunity of local treatment,including systemic chemotherapy and molecular target treatment.However,survival improvement is uncertain.AI ( ADMethe ) is still accepted as the ifrst-line chemotherapy protocol for advanced LMS,but the standerd second-line drugs and protocols are uncertain so far.Gemcitabine ( GEM ),Dacarbazine ( DTIC ) and Temozolomide ( TMZ ) can be used as second-line drugs.GEM plus Docetaxel ( TXT ) and GEM plus DTIC can be used as second-line protocols.With second-line chemotherapy failture,certain molecular target drugs may be good options such as pazopanib,sunitinib and sorafenib etc.
关键词：肉瘤平滑肌肉瘤肿瘤治疗方案放化疗
分类号：R685.6(骨科学（运动系疾病、矫形外科学）)
论文发表日期：2015-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：5( 411-415 )
英文信息